Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Companyâs proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§4027.41%ã®æé·çã瀺ããŠããŸãã
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 85.23Mã«éããŠããŸãã
é»å転æ
å瀟ã¯é»å転æãæãããææ°ã®å¹ŽéçŽå©çã¯USD ã§ãã
å²é«
åç€Ÿã®ææ°ã®PEã¯891.29ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯17.18Mæ ªã§ãåååææ¯ã§27.94%æžå°ããŠããŸãã
ETHSXãä¿æ
ã¹ã¿ãŒæè³å®¶ETHSXã¯æ¬éæã4.38Kæ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯0.08ã§ãã